Karyopharm Therapeutics (KPTI) Rating Lowered to Sell at BidaskClub

Karyopharm Therapeutics (NASDAQ:KPTI) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Thursday.

KPTI has been the subject of several other research reports. Cantor Fitzgerald set a $18.00 target price on Karyopharm Therapeutics and gave the stock a “buy” rating in a research note on Thursday, October 12th. started coverage on Karyopharm Therapeutics in a research note on Wednesday, November 15th. They set a “buy” rating and a $23.00 target price for the company. Zacks Investment Research cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 7th. Royal Bank Of Canada reissued a “buy” rating and set a $15.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Finally, ValuEngine cut Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 31st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $17.33.

Karyopharm Therapeutics (KPTI) opened at $11.11 on Thursday. Karyopharm Therapeutics has a 1 year low of $7.48 and a 1 year high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, November 2nd. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. research analysts predict that Karyopharm Therapeutics will post -2.59 EPS for the current year.

In other news, insider Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $10.39, for a total value of $103,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Mansoor Raza Mirza sold 2,882 shares of Karyopharm Therapeutics stock in a transaction on Friday, September 15th. The shares were sold at an average price of $11.00, for a total value of $31,702.00. Following the completion of the sale, the director now directly owns 2,882 shares of the company’s stock, valued at $31,702. The disclosure for this sale can be found here. Insiders sold 23,458 shares of company stock valued at $256,678 over the last ninety days. Insiders own 14.71% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Iguana Healthcare Management LLC grew its stake in shares of Karyopharm Therapeutics by 33.3% in the third quarter. Iguana Healthcare Management LLC now owns 400,000 shares of the company’s stock valued at $4,392,000 after buying an additional 100,000 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of Karyopharm Therapeutics by 21.0% in the third quarter. Schwab Charles Investment Management Inc. now owns 140,360 shares of the company’s stock valued at $1,542,000 after buying an additional 24,324 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Karyopharm Therapeutics by 753.5% in the third quarter. JPMorgan Chase & Co. now owns 307,200 shares of the company’s stock valued at $3,342,000 after buying an additional 271,208 shares in the last quarter. Candriam Luxembourg S.C.A. grew its stake in shares of Karyopharm Therapeutics by 16.4% in the third quarter. Candriam Luxembourg S.C.A. now owns 510,000 shares of the company’s stock valued at $5,600,000 after buying an additional 72,000 shares in the last quarter. Finally, Nationwide Fund Advisors grew its stake in shares of Karyopharm Therapeutics by 396.0% in the third quarter. Nationwide Fund Advisors now owns 105,664 shares of the company’s stock valued at $1,160,000 after buying an additional 84,362 shares in the last quarter. 60.92% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://ledgergazette.com/2017/12/09/karyopharm-therapeutics-kpti-rating-lowered-to-sell-at-bidaskclub.html.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply